FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BOGER JOSHUA S						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
DOGER JUSTICA 5					_   <u>M</u>	MA [ VRTX ]								)	Oirecto			10% Owner		
(Last)	(F	irst)	(Middle)											) >		Officer (give title below)		Other (specify below)		
C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 11/21/2007										Presider	nt & C	CEO		
130 WAVERLY STREET														ļ						
_					-   <sup>4.</sup>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. In Line	Individual or Joint/Group Filing (Check Applicable ne)				plicable	
(Street)  CAMBRIDGE MA 02139													)	_	iled by Mor		rting Perso One Repo	- 1		
(City)	(S	tate)	(Zip)												1 01301					
		Tab	le I - No	n-Deri	vativ	e Se	ecurit	ies Ac	quired,	Dis	posed c	of, or Be	enef	icially	y Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction [		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or P	rice	Reported Transact (Instr. 3	ion(s)			(Instr. 4)	
Common Stock				11/2	11/21/2007						17,50	0 A	.   5	\$13.67	7 1,113,342		D			
Common Stock				11/2	11/21/2007		7		S <sup>(1)(2)</sup>		800 D			323.75	5 1,112,542		D			
Common Stock				11/2	11/21/2007				S <sup>(1)(3)</sup>		1,400	1,400 D \$		323.64	1,111,142		D			
Common Stock				11/2	11/21/2007				S <sup>(1)(4)</sup>		1,400	) D	5	S23.5 <sup>4</sup>	1,10	1,109,742		D		
Common Stock 11/				11/2	11/21/2007						4,700	) D	5	S23.45	5 1,10	1,105,042		D		
Common Stock 11/2				1/200	7			S <sup>(1)(6)</sup>		3,900	) D	5	\$23.35		101,142		D			
Common Stock 11/2				1/200	7			S <sup>(1)(7)</sup>		3,100	) D		<b>323.2</b> 5	5 1,09	98,042		D			
Common Stock 11/21/				1/200	2007			S <sup>(1)(8)</sup>		1,300	) D		23.13	3 1,09	1,096,742		D			
Common Stock 11/21/				1/200	2007		S <sup>(1)(9)</sup>		900	D		S23.0 <sup>4</sup>	1,09	95,842		D				
Common Stock														12,	,445		I	401(k)		
Common Stock													207	207,500			Shares in trust <sup>(11)</sup>			
		-	Table II -								osed of, onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed Date,	4. Transaction Code (Instr 8)		5. Number 6		6. Date Expiration	. Date Exercise expiration Date Month/Day/Yea		7. Title and A of Securities Underlying Derivative Se (Instr. 3 and		ount	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Blly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisal		Expiration Date	Title	or Nu of	ount mber ares						
Stock Option	\$13.67	11/21/2007			M			17,500	(10)	1	12/11/2007	Common Stock	17	,500	<b>\$0</b>	87,686	6	D		
	n of Resnon																		-	

- 1. Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- 2. Aggregate sales made at prices between \$23.70 and \$23.80.
- 3. Aggregate sales made at prices between \$23.60 and \$23.69.
- 4. Aggregate sales made at prices between \$23.50 and \$23.59.
- 5. Aggregate sales made at prices between \$23.40 and \$23.49.
- 6. Aggregate sales made at prices between \$23.30 and \$23.39.
- 7. Aggregate sales made at prices between \$23.20 and \$23.29.
- 8. Aggregate sales made at prices between \$23.10 and \$23.19.
- 9. Aggregate sales made at prices between \$22.96 and \$23.09.
- 10. Fully vested.
- 11. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

## Remarks:

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.